MS Prevalence More Than Doubled in England (2000-2020) | UCL & Imperial Study

The number of people living with multiple sclerosis (MS) in England has more than doubled between 2000 and 2020, rising by an average of 6% each year. This significant increase isn’t necessarily due to a surge in new cases, but rather a combination of improved diagnostic techniques and the fact that people with MS are now living longer, thanks to advances in treatment and care. A new study by researchers at University College London (UCL) and Imperial College London, published in JAMA Neurology, estimates that approximately 190,000 people in England are currently living with the condition.

Understanding Multiple Sclerosis

Multiple sclerosis is a neurological condition affecting the central nervous system – the brain and spinal cord. In MS, the immune system mistakenly attacks the protective sheath (myelin) that covers nerve fibers. This damage disrupts communication between the brain and the rest of the body, leading to a wide range of potential symptoms. These can include fatigue, difficulty walking, numbness or tingling, vision problems, and cognitive difficulties. While most people are diagnosed between the ages of 20 and 50, the initial signs of MS can appear years earlier, making early diagnosis challenging.

The Role of Improved Diagnosis

The observed increase in prevalence is strongly linked to better diagnostic practices. Historically, diagnosing MS could be a lengthy process, relying on clinical assessment and excluding other conditions. Modern diagnostic tools, particularly magnetic resonance imaging (MRI), allow clinicians to detect subtle signs of MS earlier and with greater accuracy. The Queen Square Multiple Sclerosis Centre at UCL, uniting research and care at the UCL Queen Square Institute of Neurology and UCLH National Hospital for Neurology and Neurosurgery, is at the forefront of developing and utilizing these advanced MRI techniques to aid in diagnosis and understand the disease’s progression. Learn more about their work here.

Survival Rates and Contributing Factors

Alongside the rise in prevalence, the study also revealed a significant improvement in the survival rates of individuals with MS. This positive trend is attributed to advancements in disease-modifying therapies (DMTs) and overall improvements in care. DMTs aim to slow the progression of the disease and reduce the frequency of relapses. However, the research also highlighted inequalities in outcomes, with individuals in more deprived areas experiencing higher mortality rates.

Professor Olga Ciccarelli (NIHR Research Professor of Neurology, UCL Queen Square Institute of Neurology), the lead author of the study, emphasized the importance of lifestyle factors. “People with MS are living longer than ever before, thanks to better care, disease-modifying therapies, and earlier diagnosis, but there is still much more to do,” she stated. The study found that quitting smoking and maintaining a healthy weight were both associated with lower mortality rates, suggesting that addressing these modifiable risk factors could further improve outcomes.

Study Methodology and Limitations

The researchers analyzed over 30 years of public health records, utilizing a large database of primary care records in England from 1990 to 2023. Some of these records were also linked to hospital data, providing a comprehensive view of MS cases. They identified potential MS cases based on diagnostic records and prescriptions for MS-specific medications.

It’s important to note the limitations of this type of retrospective study. The accuracy of the data relies on the quality of record-keeping and coding practices over three decades. Changes in diagnostic criteria and coding systems over time could potentially influence the observed trends. The study focused specifically on England, and the findings may not be generalizable to other populations or healthcare systems. The study does not establish a causal link between improved diagnosis and increased prevalence; it demonstrates a strong association. Read the full UCL news release here.

What Does This Mean for Individuals and Public Health?

The findings underscore the importance of early diagnosis and access to effective treatments for MS. While the increased prevalence may seem alarming, it largely reflects a more accurate understanding of the disease and the ability to support individuals living with MS for longer periods. The identification of health inequalities highlights the need for targeted interventions to ensure equitable access to care and support for all individuals affected by MS, regardless of their socioeconomic background.

The study’s emphasis on lifestyle factors – smoking cessation and weight management – reinforces the importance of holistic care for people with MS. These are areas where individuals can actively participate in managing their health and potentially improving their long-term outcomes.

The Ongoing Research Landscape

Research into MS continues at a rapid pace. The Queen Square Multiple Sclerosis Centre, for example, is actively involved in understanding the underlying disease mechanisms, identifying new treatment strategies, and developing innovative clinical trial designs. News-Medical.net provides further coverage of the study. This includes exploring potential biomarkers – measurable indicators of disease activity – that could help predict clinical outcomes and monitor treatment response.

Next Steps: Surveillance and Guidance Updates

Public health surveillance of MS prevalence and mortality will continue to be crucial for monitoring trends and evaluating the impact of interventions. The National Health Service (NHS) and Public Health England (now UK Health Security Agency) regularly review data on neurological conditions, including MS, to inform guidance and resource allocation. Ongoing clinical trials are evaluating new and emerging therapies for MS, with the potential to further improve outcomes in the future. Individuals with concerns about MS are encouraged to consult with a qualified healthcare professional for personalized advice and support.